Skip to main navigation Skip to search Skip to main content

Long-term renal outcomes comparison between patients with chronic kidney disease and hepatorenal syndrome after living donor liver transplantation

  • Hsiang Yu Tseng
  • , Yu Hung Lin
  • , Chih Che Lin
  • , Chao Long Chen
  • , Chee Chien Yong
  • , Li Man Lin
  • , Chih Chi Wang
  • , Yi Chia Chan*
  • *Corresponding author for this work
  • Chang Gung University
  • Cheng Shiu University Taiwan

Research output: Contribution to journalJournal Article peer-review

2 Scopus citations

Abstract

BACKGROUND AND AIMS: Hepatorenal syndrome (HRS) is a disastrous renal complication of advanced liver disease with a poor prognosis. Restoring normal liver function through liver transplantation (LT) is a standardized treatment with favorable short-term survival. However, the long-term renal outcomes in patients with HRS receiving living donor LT (LDLT) are controversial. This study aimed to investigate the prognostic impact of LDLT in patients with HRS.

METHODS: We reviewed adult patients who underwent LDLT between July 2008 and September 2017. Recipients were classified into 1) HRS type 1 (HRS1, N  = 11), 2) HRS type 2 (HRS2, N  = 19), 3) non-HRS recipients with pre-existing chronic kidney disease (CKD, N  = 43), and 4) matched normal renal function ( N  = 67).

RESULTS: Postoperative complications and 30-day surgical mortality were comparable among the HRS1, HRS2, CKD, and normal renal function groups. The 5-year survival rate was >90% and estimated glomerular filtration rate (eGFR) transiently improved and peaked at 4 weeks post-transplantation in patients with HRS. However, renal function deteriorated and resulted in CKD stage ≥ III in 72.7% of HRS1 and 78.9% of HRS2 patients (eGFR <60 ml/min/1.73 m 2). The incidence of developing CKD and end-stage renal disease (ESRD) was similar between the HRS1, HRS2, and CKD groups, but significantly higher than that in the normal renal function group (both P  < 0.001). In multivariate logistic regression, pre-LDLT eGFR <46.4 ml/min/1.73 m 2 predicted the development of post-LDLT CKD stage ≥ III in patients with HRS (AUC = 0.807, 95% CI = 0.617-0.997, P  = 0.011).

CONCLUSIONS: LDLT provides a significant survival benefit for patients with HRS. However, the risk of CKD stage ≥ III and ESRD among patients with HRS was similar to that in pre-transplant CKD recipients. An early preventative renal-sparing strategy in patients with HRS is recommended.

Original languageEnglish
Article number1116728
Pages (from-to)1116728
JournalFrontiers in Surgery
Volume10
DOIs
StatePublished - 2023

Bibliographical note

© 2023 Tseng, Lin, Lin, Chen, Yong, Lin, Wang and Chan.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • chronic kidney disease (CKD)
  • end-stage liver disease (ESRD)
  • hepatorenal syndrome (HRS)
  • liver transplantation (LT)
  • living donor LT (LDLT)

Fingerprint

Dive into the research topics of 'Long-term renal outcomes comparison between patients with chronic kidney disease and hepatorenal syndrome after living donor liver transplantation'. Together they form a unique fingerprint.

Cite this